Get started
Author

Ariel Felipe Grajales-Cruz

Observed names: A. Grajales-Cruz, Ariel F Grajales-Cruz, Ariel F. Grajales-Cruz, Ariel F. Grajales‐Cruz, Ariel Grajales, Ariel Grajales Cruz, Ariel Grajales-Cruz, Ariel Grajales-cruz, Ariel Grajales‐Cruz, Grajales-Cruz A, Grajales-Cruz, Ariel F., Grajales-Cruz, Ariel, MD
ORCID: 0000-0003-0999-1771
Observed ORCID: 0000-0003-0999-1771
OpenAlex ID: A5082565225
Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK Inhibition as an Effective Strategy
2020 · Anthony R. Mato, Lindsey E. Roeker, et al. · Clinical Cancer Research · 117
Early cytopenias and infections after standard of care idecabtagene vicleucel in relapsed or refractory multiple myeloma
2022 · Jennifer M. Logue, Lauren C. Peres, et al. · Blood Advances · 100
PDF
Tumor burden quantified by soluble B-cell maturation antigen and metabolic tumor volume determines myeloma CAR-T outcomes
2024 · Ciara L. Freeman, Jerald Noble, et al. · Blood · 43
Sequential targeting in multiple myeloma: talquetamab, a GPRC5D bispecific antibody, as a bridge to BCMA CAR-T therapy
2025 · Binod Dhakal, Othman S. Akhtar, et al. · Blood · 39
Safety and efficacy of anti-BCMA CAR-T cell therapy in older adults with multiple myeloma: A systematic review and meta-analysis
2023 · Othman Salim Akhtar, Ba Aqeel Sheeba, et al. · Journal of Geriatric Oncology · 30
Cardiac events after standard of care idecabtagene vicleucel for relapsed and refractory multiple myeloma
2023 · Dae Hyun Lee, Abhishek Kumar, et al. · Blood Advances · 28
PDF
Simple Score of Albumin and CRP Predicts High-Grade Toxicity in Patients with Multiple Myeloma Receiving CAR-T Therapy
2023 · Othman S. Akhtar, Karnav Modi, et al. · Transplantation and Cellular Therapy · 24
Real-World Experience with Teclistamab for Relapsed/Refractory Multiple Myeloma from the US Myeloma Immunotherapy Consortium
2025 · Beatrice M. Razzo, Shonali Midha, et al. · Blood Cancer Discovery · 22
Talquetamab Bridging: Paving the Way to B-Cell Maturation Antigen (BCMA) CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma (RRMM)
2024 · Binod Dhakal, Othman S. Akhtar, et al. · Blood · 20
Outcomes of teclistamab in patients with relapsed/refractory multiple myeloma with prior exposure to BCMA-directed therapy: a multicenter study from the U.S. Multiple Myeloma Immunotherapy Consortium
2025 · Danai Dima, Mariola A. Vazquez-Martinez, et al. · Blood Cancer Journal · 18
PDF
Primary Adrenal Angiosarcoma: A Rare and Potentially Misdiagnosed Tumor
2017 · Ariel Grajales-Cruz, Francis Baco-Viera, et al. · Cancer Control · 17
High Metabolic Tumor Volume Is Associated with Higher Toxicity and Decreased Efficacy of BCMA CAR-T Cell Therapy in Multiple Myeloma
2022 · Ricardo Villanueva, Doris K. Hansen, et al. · Blood · 16
Teclistamab for patients with heavily pretreated relapsed/refractory multiple myeloma and renal impairment
2025 · Danai Dima, Aimaz Afrough, et al. · Blood Advances · 12
PDF
Outcomes of elderly patients with relapsed refractory multiple myeloma (RRMM) treated with teclistamab: a multicenter study from the U.S. Multiple Myeloma Immunotherapy Consortium
2025 · Oren Pasvolsky, Danai Dima, et al. · Blood Cancer Journal · 11
PDF
Outcomes of Teclistamab (Tec) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) with Prior Exposure to BCMA-Directed Therapy (BCMA-DT): A Multicenter Study from the U.S. Multiple Myeloma Immunotherapy Consortium
2024 · Danai Dima, Mariola A Vazquez-Martinez, et al. · Blood · 9
Teclistamab Induces Favorable Responses in Patients with Relapsed and Refractory Multiple Myeloma after Prior BCMA-Directed Therapy
2023 · Ariel F. Grajales-Cruz, Omar Castaneda, et al. · Blood · 8
Patient-Reported Outcomes among Multiple Myeloma Patients Treated with Standard of Care Idecabtagene Vicleucel
2023 · Laura B. Oswald, Lisa M. Gudenkauf, et al. · Cancers · 8
PDF
Association of frailty and high-risk immuno-nutritional score with outcomes in patients with relapsed and refractory multiple myeloma treated with chimeric antigen receptor T-cells.
2023 · Karnav Modi, Othman Salim Akhtar, et al. · Journal of Clinical Oncology · 8
PDF
Classical Hodgkin Lymphoma: Clinicopathologic Features, Prognostic Factors, and Outcomes From a 28-Year Single Institutional Experience
2020 · Ashley Rose, Ariel Grajales-Cruz, et al. · Clinical Lymphoma Myeloma & Leukemia · 8
Elotuzumab in Combination with an Immunomodulatory Agent (IMID) in Patients with Multiple Myeloma Refractory to Imids and/or Daratumumab: A Single-Institution Analysis
2019 · Ariel F Grajales-Cruz, Cristian Ivan Rodriguez Arocho, et al. · Blood · 8
Real-world outcomes with elranatamab in multiple myeloma: a multicenter analysis from the U.S. Multiple Myeloma Immunotherapy Consortium
2026 · Andrew J. Portuguese, James A. Davis, et al. · Blood Cancer Journal · 7
PDF
Enhancing the safety of ciltacabtagene autoleucel in relapsed multiple myeloma (MM): Identification of potentially modifiable risk-factors associated with delayed neurotoxicity and non-relapse mortality
2025 · Surbhi Sidana, Brett Reid, et al. · Blood · 7
Real-world outcomes with elranatamab in multiple myeloma: A multi-center analysis from the United States multiple myeloma immunotherapy consortium
2025 · Andrew Portuguese, James Davis, et al. · Blood · 7
PDF
B‐cell maturation antigen expression and clinical features of plasmablastic lymphoma
2024 · Ning Dong, Hailing Zhang, et al. · eJHaem · 7
PDF
Outcomes of patients with relapsed/refractory lymphoplasmacytic lymphoma/waldenström macroglobulinemia treated with venetoclax: a multicenter retrospective analysis
2025 · Y. Sawalha, S. Sarosiek, et al. · Blood Cancer Journal · 6
PDF
Works count: 209
Citation count: 746
H-index: 12
I10-index: 14
Year
Topic
Type